Qlt Inc.

Novartis Ag

Qlt Phototherapeutics, Inc.

Other

Valeant Pharmaceuticals International

Novelion Therapeutics Inc.

Novartis Opthalmics Ag

Retinagenix Therapeutics, Inc.

Bausch Health Companies Inc.

H Andrew Strong

Julia G Levy

Ronald Erwin Boch

Gustav Huber

Mario Fsadni

Janice North

Suzanne Cadden

Yong Hao

Troy Albert Reaves, Jr

Peter Hnik

Mohammad Azab

John Miller Koester

Troy Albert Reaves

Mohammad Azad

Troy Albert Reaves Jr

Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.

Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency

The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.

Photodynamic therapy for conditions of the eye

Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.

Vision through photodynamic therapy of the eye

The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).

Photodynamic therapy of occult age-related macular degeneration

The invention relates to the use of reduced fluency rate PDT to treat neovasculature, particularly choroidal neovasculature (CNV). Reduced fluency rate PDT decreases the likelihood of molecular oxygen being the limiting factor in the photodynamic reaction so that the concentration of either photons (light intensity) or photosensitizer in the target tissue controls the photodynamic reaction.

Reduced fluence rate PDT

An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.

Method to prevent vision loss

The invention relates to the use of photodynamic therapy (PDT) to treat macular edemas, including DME, CRVO and BRVO. It provides an alternative to photocoagulation and the disadvantages associated therewith.

Treatment of macular edema

The invention relates to the use of reduced fluence rate PDT to treat neovasculature, particularly choroidal neovasculature (CNV). Reduced fluence rate PDT decreases the likelihood of molecular oxygen being the limiting factor in the photodynamic reaction so that the concentration of either photons (light intensity) or photosensitizer in the target tissue controls the photodynamic reaction.

Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects,

Growing community of inventors

Vancouver, Canada

H Andrew Strong